List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/915147/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of high-endurance exercise intervention on sleep-dependent procedural memory consolidation in individuals with schizophrenia: a randomized controlled trial. Psychological Medicine, 2023, 53, 1708-1720.	4.5	9
2	Impact of restrictive COVID-19 measures on daily momentary affect in an epidemiological youth sample in Hong Kong: An experience sampling study. Current Psychology, 2023, 42, 20804-20813.	2.8	4
3	Prevalence and correlates of suicidal behaviours in a representative epidemiological youth sample in Hong Kong: the significance of suicide-related rumination, family functioning, and ongoing population-level stressors. Psychological Medicine, 2023, 53, 4603-4613.	4.5	8
4	Elucidating the relationship between internalized stigma, cognitive insight, illness severity, and functioning in patients with schizophrenia using a path analysis approach. Journal of Mental Health, 2022, 31, 29-38.	1.9	4
5	Investigation of motor self-monitoring deficits in schizophrenia with passivity experiences using a novel modified joint position matching paradigm. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 509-518.	3.2	0
6	The impact of social unrest and pandemic on mental health of young people in Hong Kong: The transdiagnostic role of event-based rumination. Australian and New Zealand Journal of Psychiatry, 2022, 56, 376-384.	2.3	14
7	Motivational coaching augmentation of exercise intervention for early psychotic disorders: A randomised controlled trial. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1277-1286.	2.3	3
8	Stressful events as correlates of depressive and PTSD symptoms in Hong Kong women during social unrest and COVID-19 pandemic. Journal of Affective Disorders, 2022, 300, 263-268.	4.1	2
9	Explicit and implicit mentalization of patients with first-episode schizophrenia: a study of self-referential gaze perception with eye movement analysis using hidden Markov models. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	3.2	3
10	Effectiveness and optimal duration of early intervention treatment in adult-onset psychosis: a randomized clinical trial. Psychological Medicine, 2022, , 1-13.	4.5	3
11	Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder. Psychopharmacology, 2022, 239, 2133-2141.	3.1	4
12	Longitudinal relapse pattern of patients with first-episode schizophrenia-spectrum disorders and its predictors and outcomes: A 10-year follow-up study. Asian Journal of Psychiatry, 2022, 71, 103087.	2.0	4
13	Correlates and predictors of perceived stigma and selfâ€stigma in Chinese patients with psychosis. Microbial Biotechnology, 2022, 16, 1075-1084.	1.7	3
14	<scp>LevelMind</scp> @ <scp>JC</scp> : Development and evaluation of a community early intervention program for young people in Hong Kong. Microbial Biotechnology, 2022, 16, 920-925.	1.7	4
15	Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review. International Journal of Neuropsychopharmacology, 2022, 25, 737-758.	2.1	3
16	Dynamic Patterns of Symptoms and Functioning in Predicting Deliberate Self-harm in Patients with First-Episode Schizophrenia-Spectrum Disorders Over 3 Years. Schizophrenia Bulletin, 2022, 48, 1043-1052.	4.3	1
17	The 12-month prevalence of psychotic experiences and their association with clinical outcomes in Hong Kong: an epidemiological and a 2-year follow up studies. Psychological Medicine, 2021, 51, 2501-2508.	4.5	9
18	Effect of brief social contact video compared with expert information video in changing knowledge and attitude towards psychosis patients among medical students. Microbial Biotechnology, 2021, 15, 278-285.	1.7	8

CHRISTY LM HUI

#	Article	IF	CITATIONS
19	Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. Schizophrenia Bulletin, 2021, 47, 485-494.	4.3	42
20	The Latent Structure of Negative Symptoms in Individuals With Attenuated Psychosis Syndrome and Early Psychosis: Support for the 5 Consensus Domains. Schizophrenia Bulletin, 2021, 47, 386-394.	4.3	28
21	Relationship between stressful life events, stigma and life satisfaction with the willingness of disclosure of psychotic illness: A community study in Hong Kong. Microbial Biotechnology, 2021, 15, 686-696.	1.7	6
22	Integration of biological and psychological illness attributional belief in association with medication adherence behaviour: A path analysis. Microbial Biotechnology, 2021, 15, 1686-1695.	1.7	2
23	The predictive power of expressed emotion and its components in relapse of schizophrenia: a meta-analysis and meta-regression. Psychological Medicine, 2021, 51, 365-375.	4.5	32
24	Self-referential gaze perception of patients with schizophrenia and its relationship with symptomatology and cognitive functions. Schizophrenia Research, 2021, 228, 288-294.	2.0	4
25	Relationship between subjective quality of life and perceptions of recovery orientation of treatment service in patients with schizophrenia and major depressive disorder. Asian Journal of Psychiatry, 2021, 57, 102578.	2.0	2
26	Prospective prediction of PTSD and depressive symptoms during social unrest and COVID-19 using a brief online tool. Psychiatry Research, 2021, 298, 113773.	3.3	21
27	Sociodemographic correlates of public stigma about mental illness: a population study on Hong Kong's Chinese population. BMC Psychiatry, 2021, 21, 274.	2.6	12
28	Patterns and predictors of trajectories for subjective quality of life in patients with early psychosis: Three-year follow-up of the randomized controlled trial on extended early intervention. Australian and New Zealand Journal of Psychiatry, 2021, 55, 983-992.	2.3	5
29	LevelMind @ JC hubs–a novel communityâ€based youth mental wellness early intervention in Hong Kong: An evaluation of stakeholders' perceptions and experiences. Microbial Biotechnology, 2021, , .	1.7	0
30	Relationship of subjective quality of life with symptomatology, neurocognition and psychosocial functioning in first-episode psychosis: a structural equation modelling approach. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1561-1569.	3.2	5
31	Mindfulness meditation for Chinese patients with psychosis: A systematic review and meta-analysis. Schizophrenia Research, 2021, 237, 103-114.	2.0	8
32	Mental Health Risks after Repeated Exposure to Multiple Stressful Events during Ongoing Social Unrest and Pandemic in Hong Kong: The Role of Rumination: Risques pour la santé mentale après une exposition répétée à de multiples événements stressants d'agitation sociale durable et de pandÃ Hong Kong: le rÃ1e de la rumination. Canadian Journal of Psychiatry, 2021, 66, 577-585.	©mie Ã	24
33	<scp>ReMind</scp> , a smartphone application for psychotic relapse prediction: A longitudinal study protocol. Microbial Biotechnology, 2021, 15, 1659-1666.	1.7	4
34	A multifaceted approach in promoting positive mental health culture in Hong Kong secondary schools: The Mindshift educational networking programme. Microbial Biotechnology, 2021, , .	1.7	0
35	Ten-year employment patterns of patients with first-episode schizophrenia-spectrum disorders: comparison of early intervention and standard care services. British Journal of Psychiatry, 2020, 217, 491-497.	2.8	9
36	The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders. Neuropsychopharmacology, 2020, 45, 1870-1876.	5.4	22

#	Article	IF	CITATIONS
37	Perspective on medication decisions following remission from first-episode psychosis. Schizophrenia Research, 2020, 225, 82-89.	2.0	5
38	Ten-year trajectory and outcomes of negative symptoms of patients with first-episode schizophrenia spectrum disorders. Schizophrenia Research, 2020, 220, 85-91.	2.0	16
39	Executive dysfunctions differentially predict amotivation in first-episode schizophrenia-spectrum disorder: a prospective 1-year follow-up study. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 887-896.	3.2	5
40	Ten-year follow up of patients with first-episode schizophrenia spectrum disorder from an early intervention service: Predictors of clinical remission and functional recovery. Schizophrenia Research, 2019, 204, 65-71.	2.0	29
41	Early-Stage Negative Symptom Trajectories and Relationships With 13-Year Outcomes in First-Episode Nonaffective Psychosis. Schizophrenia Bulletin, 2019, 45, 610-619.	4.3	38
42	Destigmatizing psychosis: Investigating the effectiveness of a schoolâ€based programme in Hong Kong secondary school students. Microbial Biotechnology, 2019, 13, 882-887.	1.7	11
43	Late-onset psychosis and very-late-onset-schizophrenia-like-psychosis: an updated systematic review. International Review of Psychiatry, 2019, 31, 523-542.	2.8	26
44	A systematic review of long-term outcomes of patients with psychosis who received early intervention services. International Review of Psychiatry, 2019, 31, 425-440.	2.8	23
45	Systematic review (meta-aggregation) of qualitative studies on the experiences of family members caring for individuals with early psychosis. International Review of Psychiatry, 2019, 31, 491-509.	2.8	7
46	A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia. International Review of Psychiatry, 2019, 31, 441-459.	2.8	27
47	Spontaneous eye blink in patients with psychosis in perceptions of stimulus salience. Schizophrenia Research, 2019, 209, 275-277.	2.0	0
48	Effort-based decision-making impairment in patients with clinically-stabilized first-episode psychosis and its relationship with amotivation and psychosocial functioning. European Neuropsychopharmacology, 2019, 29, 629-642.	0.7	31
49	Gender differences in correlates of cognition in first-episode psychosis. Psychiatry Research, 2019, 271, 412-420.	3.3	27
50	Psychiatrists' opinion towards medication discontinuation in remitted firstâ€episode psychosis: A multiâ€site study of the Asian Network for Early Psychosis. Microbial Biotechnology, 2019, 13, 1329-1337.	1.7	10
51	The role of symptoms and insight in mediating cognition and functioning in first episode psychosis. Schizophrenia Research, 2019, 206, 251-256.	2.0	17
52	Predicting first-episode psychosis patients who will never relapse over 10 years. Psychological Medicine, 2019, 49, 2206-2214.	4.5	22
53	Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis. JAMA Psychiatry, 2019, 76, 217.	11.0	6
54	Relationship between neurocognitive function and clinical symptoms with self-stigma in patients with schizophrenia-spectrum disorders. Journal of Mental Health, 2019, 28, 583-588.	1.9	21

CHRISTY LM HUI

#	Article	IF	CITATIONS
55	Clinical and functional correlates of financially deprived women with firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 639-645.	1.7	4
56	Rates and predictors of disengagement of patients with firstâ€episode psychosis from the early intervention service for sychosis service (EASY) covering 15 to 64 years of age in Hong Kong. Microbial Biotechnology, 2019, 13, 398-404.	1.7	11
57	Motivational impairment predicts functional remission in first-episode psychosis: 3-Year follow-up of the randomized controlled trial on extended early intervention. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1194-1201.	2.3	16
58	Suicide Rates, Psychiatric Hospital Bed Numbers, and Unemployment Rates From 1999 to 2015: A Population-Based Study in Hong Kong. American Journal of Psychiatry, 2018, 175, 285-286.	7.2	5
59	Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders. JAMA Psychiatry, 2018, 75, 458.	11.0	57
60	Patterns and predictors of trajectories for social and occupational functioning in patients presenting with first-episode non-affective psychosis: A three-year follow-up study. Schizophrenia Research, 2018, 197, 131-137.	2.0	31
61	Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis. JAMA Psychiatry, 2018, 75, 555.	11.0	516
62	Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry,the, 2018, 5, 432-442.	7.4	97
63	Prevalence and correlates of antipsychotic polypharmacy in Hong Kong. Asian Journal of Psychiatry, 2018, 33, 113-120.	2.0	17
64	Long term effect of early intervention service on duration of untreated psychosis in youth and adult population in <scp>H</scp> ong <scp>K</scp> ong. Microbial Biotechnology, 2018, 12, 331-338.	1.7	11
65	Demographic correlates of medication knowledge in Hong Kong early psychosis patients. Microbial Biotechnology, 2018, 12, 107-112.	1.7	3
66	Early intervention for incipient insanity: early notions from the 19 <sup>th</sup> century English literature. Microbial Biotechnology, 2018, 12, 708-714.	1.7	1
67	Predictors of functioning in people suffering from firstâ€episode psychosis 1 year into entering early intervention service in Hong Kong. Microbial Biotechnology, 2018, 12, 828-838.	1.7	1
68	Perception towards relapse and its predictors in psychosis patients: A qualitative study. Microbial Biotechnology, 2018, 12, 856-862.	1.7	8
69	Prediction of self-stigma in early psychosis: 3-Year follow-up of the randomized-controlled trial on extended early intervention. Schizophrenia Research, 2018, 195, 463-468.	2.0	26
70	Chinese label for people at risk for psychosis. Microbial Biotechnology, 2017, 11, 224-228.	1.7	3
71	Newspaper coverage of mental illness in <scp>H</scp> ong <scp>K</scp> ong between 2002 and 2012: impact of introduction of a new <scp>C</scp> hinese name of psychosis. Microbial Biotechnology, 2017, 11, 342-345.	1.7	15
72	Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis. Psychiatry Research, 2017, 249, 39-45.	3.3	13

CHRISTY LM HUI

#	Article	IF	CITATIONS
73	Yoga reduces the brain's amplitude of low-frequency fluctuations in patients with early psychosis results of a randomized controlled trial. Schizophrenia Research, 2017, 184, 141-142.	2.0	17
74	Sustainability of treatment effect of a 3-year early intervention programme for first-episode psychosis. British Journal of Psychiatry, 2017, 211, 37-44.	2.8	35
75	Web-Based Psychoeducation Program for Caregivers of First-Episode of Psychosis: An Experience of Chinese Population in Hong Kong. Frontiers in Psychology, 2016, 07, 2006.	2.1	21
76	A Lowâ€Intensity Mindfulnessâ€Based Intervention for Mood Symptoms in People with Early Psychosis: Development and Pilot Evaluation. Clinical Psychology and Psychotherapy, 2016, 23, 550-560.	2.7	21
77	Examining gender difference in adultâ€onset psychosis in Hong Kong. Microbial Biotechnology, 2016, 10, 324-333.	1.7	19
78	Prediction of functional remission in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong. Schizophrenia Research, 2016, 173, 79-83.	2.0	29
79	Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis. Schizophrenia Research, 2016, 174, 144-149.	2.0	30
80	Self-stigma and affiliate stigma in first-episode psychosis patients and their caregivers. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 1225-1231.	3.1	40
81	Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia. Journal of Affective Disorders, 2016, 200, 1-5.	4.1	17
82	Antipsychotic Treatment of Young Chinese Individuals From 2004 to 2015: A Population-Based Study in Hong Kong. American Journal of Psychiatry, 2016, 173, 939-940.	7.2	2
83	Incidence of hospitalization and its associated factors in firstâ€episode psychosis in <scp>H</scp> ong <scp>K</scp> ong. Microbial Biotechnology, 2016, 10, 263-266.	1.7	1
84	Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis. Psychiatry Research, 2016, 242, 144-149.	3.3	24
85	Public Stigma in China Associated With Schizophrenia, Depression, Attenuated Psychosis Syndrome, and Psychosis-Like Experiences. Psychiatric Services, 2016, 67, 766-770.	2.0	38
86	Quality of life and functioning in firstâ€episode psychosis <scp>C</scp> hinese patients with different antipsychotic medications. Microbial Biotechnology, 2016, 10, 535-539.	1.7	4
87	Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study. Schizophrenia Research, 2016, 170, 318-321.	2.0	44
88	A systematic review on definitions and assessments of psychoticâ€like experiences. Microbial Biotechnology, 2016, 10, 3-16.	1.7	78
89	A population study of public stigma about psychosis and its contributing factors among Chinese population in Hong Kong. International Journal of Social Psychiatry, 2016, 62, 205-213.	3.1	23
90	The Effect of Paternal Age on Relapse in First-Episode Schizophrenia. Canadian Journal of Psychiatry, 2015, 60, 346-353.	1.9	10

#	Article	IF	CITATIONS
91	Aerobic exercise and yoga improve neurocognitive function in women with early psychosis. NPJ Schizophrenia, 2015, 1, 15047.	3.6	84
92	Optimal duration of an early intervention programme for first-episode psychosis: randomised controlled trial. British Journal of Psychiatry, 2015, 206, 492-500.	2.8	63
93	Psychosis patients' knowledge, adherence and attitudes towards the naming of antipsychotic medication in <scp>H</scp> ong <scp>K</scp> ong. Microbial Biotechnology, 2015, 9, 422-427.	1.7	13
94	Prevalence and predictors of medication non-adherence among Chinese patients with first-episode psychosis. Psychiatry Research, 2015, 228, 680-687.	3.3	12
95	Perceived risk of relapse and role of medication: comparison between patients with psychosis and their caregivers. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 307-315.	3.1	15
96	Prevalence and risk factors for violent behavior in young people presenting with first-episode psychosis in Hong Kong: A 3-year follow-up study. Australian and New Zealand Journal of Psychiatry, 2015, 49, 914-922.	2.3	23
97	Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong. Schizophrenia Research, 2015, 168, 99-105.	2.0	24
98	Self-perceived cognitive functioning and its relationship with objective performance in first-episode schizophrenia: The Subjective Cognitive Impairment Scale. Comprehensive Psychiatry, 2015, 56, 42-50.	3.1	16
99	Clinical and social correlates of duration of untreated psychosis among adultâ€onset psychosis in <scp>H</scp> ong <scp>K</scp> ong <scp>C</scp> hinese: the <scp>JCEP</scp> study. Microbial Biotechnology, 2015, 9, 118-125.	1.7	31
100	Early Medication Discontinuation on Long-term Recovery Outcome in First-Episode Psychosis. JAMA Psychiatry, 2014, 71, 207.	11.0	4
101	Early intervention and evaluation for adultâ€onset psychosis: the <scp>JCEP</scp> study rationale and design. Microbial Biotechnology, 2014, 8, 261-268.	1.7	38
102	Coupling physical exercise with dietary glucose supplement for treating cognitive impairment in schizophrenia: a theoretical model and future directions. Microbial Biotechnology, 2014, 8, 209-220.	1.7	11
103	Comparing illness presentation, treatment and functioning between patients with adolescent- and adult-onset psychosis. Psychiatry Research, 2014, 220, 797-802.	3.3	24
104	Clinical and cognitive predictors of vocational outcome in first-episode schizophrenia: A prospective 3 year follow-up study. Psychiatry Research, 2014, 220, 834-839.	3.3	25
105	Medication Adherence, Knowledge About Psychosis, and Insight Among Patients With a Schizophrenia-Spectrum Disorder. Journal of Nervous and Mental Disease, 2014, 202, 25-29.	1.0	23
106	Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: A first-episode psychosis study. Schizophrenia Research, 2014, 153, 1-8.	2.0	53
107	Executive function as predictors of persistent thought disorder in first-episode schizophrenia: A one-year follow-up study. Schizophrenia Research, 2014, 159, 465-470.	2.0	28
108	The relationships of suicidal ideation with symptoms, neurocognitive function, and psychological factors in patients with first-episode psychosis. Schizophrenia Research, 2014, 157, 12-18.	2.0	46

#	Article	IF	CITATIONS
109	Relationship between diminished expression and cognitive impairment in first-episode schizophrenia: A prospective three-year follow-up study. Schizophrenia Research, 2014, 152, 146-151.	2.0	16
110	Predictors of help-seeking duration in adult-onset psychosis in Hong Kong. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1819-1828.	3.1	13
111	Reliability and validity of the life functioning assessment inventory (L-FAI) for patients with psychosis. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 1687-1695.	3.1	4
112	Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis. Schizophrenia Research, 2013, 150, 297-302.	2.0	24
113	A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong. Australian and New Zealand Journal of Psychiatry, 2013, 47, 746-753.	2.3	35
114	Longitudinal changes in semantic categorization performance after symptomatic remission from first-episode psychosis: A 3-year follow-up study. Schizophrenia Research, 2012, 137, 118-123.	2.0	7
115	Executive function in first-episode schizophrenia: A three-year longitudinal study of an ecologically valid test. Schizophrenia Research, 2011, 126, 87-92.	2.0	30
116	Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: a comparison between nursing and social work professionals. Microbial Biotechnology, 2011, 5, 324-334.	1.7	2
117	Three-year outcome of phase-specific early intervention for first-episode psychosis: a cohort study in Hong Kong. Microbial Biotechnology, 2011, 5, 315-323.	1.7	64
118	Early intervention for psychosis in Hong Kong – the EASY programme. Microbial Biotechnology, 2010, 4, 214-219.	1.7	62
119	Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ: British Medical Journal, 2010, 341, c4024-c4024.	2.3	125
120	Potential endophenotype for schizophrenia: neurological soft signs. Annals of the Academy of Medicine, Singapore, 2009, 38, 408-6.	0.4	5
121	Real-world implementation of early intervention in psychosis: resources, funding models and evidence-based practice. World Psychiatry, 2008, 7, 163-164.	10.4	9
122	Anti-psychotics adherence among out-patients with schizophrenia in Hong Kong. Keio Journal of Medicine, 2006, 55, 9-14.	1.1	41
123	A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophrenia Research, 2005, 77, 99-104.	2.0	106